Company / Net Income
Sarepta Therapeutics Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$713.4M
FY2025
5-year range
-$713.4M / $235.2M
FY2021-FY2025
Trend
-403.3%
vs FY2024
Sector context
#204 of 216
Health Care
What the data says
Net Income changed -403% YoY in FY2025, a notable deviation from the 9-year average annual change of -152%.
Based on SEC 10-K filings.
-$713M in FY2025.
Declined from -$536M to -$713M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 216This company -$713.4M Sector average $454.3M
▼
-257.0% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 403.3% year-over-year.
- Ranks #204 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$713.4M | -403.3% |
| FY2024 | $235.2M | +143.9% |
| FY2023 | -$536.0M | +3.3% |
| FY2022 | -$554.1M | -32.3% |
| FY2021 | -$418.8M | -15.7% |
| FY2020 | -$361.9M | -614.0% |
| FY2019 | -$50.7M | +86.0% |
| FY2018 | -$361.9M | -614.0% |
| FY2017 | -$50.7M | +81.0% |
| FY2016 | -$267.3M | -21.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026